Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy

Journal of Clinical Immunology

Volumn 34, Issue 4, 2014, Pages 504-513

  Andrabi, Raiees ^a   Makhdoomi, M A ^a   Kumar, Rajesh ^a   Bala, Manju ^b   Parray, Hilal ^a   Gupta, Arjun ^a   Kotnala, Ankita ^a   Thirumurthy, Velpandian ^a   Luthra, Kalpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

antiretroviral therapy; HIV 1; neutralizing antibodies

Indexed keywords

IMMUNOGLOBULIN G; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RECOMBINANT GLYCOPROTEIN GP 120; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; CLINICAL ARTICLE; CROSS REACTION; DILUTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS NEUTRALIZATION; BLOOD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOLOGY; MIDDLE AGED; SERODIAGNOSIS; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VIRAL LOAD;

EID: 84901388484     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0010-y     Document Type: Article

References (57)

1. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173(2):340-8. (Pubitemid 26042433)
2. Graham BS. Clinical trials of HIV vaccines. Annu Rev Med. 2002;53:207-21. (Pubitemid 34177879)
3. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med. 2003;9(7):874-80. (Pubitemid 36889929)
4. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5(3):233-6. (Pubitemid 38332116)
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20.
6. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86.
7. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008;82(23):11651-68.
8. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol. 2009;83(1):188-99.
9. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009;83(2):757-69.
10. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009;83(14):7337-48.
11. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009;15(8):866-70.
12. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, McClelland RS, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83(19):10269-74.
13. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2010;84(3):1631-6.
14. Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK, et al. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr. 2011;57(1):9-15.
15. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007;13(9):1032-4. (Pubitemid 47517505)
16. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563-71. (Pubitemid 351321534)
17. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458(7238):636-40.
18. Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011;85(12):5804-13.
19. Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181(1):358-63. (Pubitemid 30049071)
20. Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, et al. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retrovir. 2001;17(11):1003-8. (Pubitemid 32881319)
21. Kimura T, Yoshimura K, Nishihara K, Maeda Y, Matsumi S, Koito A, et al. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis. 2002;185(1):53-60. (Pubitemid 34043016)
22. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44(5):749-54.
23. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIVinfection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571-9.
24. Choudhary AK, Andrabi R, Prakash SS, Kumar R, Choudhury SD, Wig N, et al. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy. J Microbiol. 2012;50(1):149-54.
25. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12(17):F217-23. (Pubitemid 28526400)
26. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41(7):1045-8. (Pubitemid 41368231)
27. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197(4):572-9. (Pubitemid 351321535)
28. Sarmati L, Nicastri E, el-Sawaf G, Ventura L, Salanitro A, Ercoli L, et al. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J Med Virol. 1997;53(4):313-8. (Pubitemid 28228355)
29. Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIVinfection. AIDS Res Hum Retrovir. 2001;17(11):1021-34. (Pubitemid 32881321)
30. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol. 2009;83(17):8925-37.
31. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010;201(7):1045-53.
32. Shankarappa R, Chatterjee R, Learn GH, Neogi D, Ding M, Roy P, et al. Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J Virol. 2001;75(21):10479-87. (Pubitemid 32948079)
33. Jere A, Tripathy S, Agnihotri K, Jadhav S, Paranjape R. Genetic analysis of Indian HIV-1 nef: subtyping, variability and implications. Microbes Infect. 2004;6(3):279-89. (Pubitemid 38327139)
34. Andrabi R, Kumar R, Bala M, Nair A, Ss P, Kushwaha V, et al. Envelope diversity, characteristics of V3 region and predicted co-receptor usage of human immunodeficiency viruses infecting north Indians. J Microbiol. 2012;50(5):869-73.
35. Dutta Choudhury S, Chaudhury AK, Kalra R, Andrabi R, Wig N, Biswas A, et al. Antiretroviral drug resistance mutations in the reverse transcriptase gene of HIV-1 isolates from Northern Indian patients: a follow-up study. Arch Virol. 2010;155(4):563-9.
36. Mascola JR, Louder MK, Winter C, Prabhakara R, De Rosa SC, Douek DC, et al. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol. 2002;76(10):4810-21. (Pubitemid 34441687)
37. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16):10108-25. (Pubitemid 41098552)
38. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439-52.
39. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;Chapter 12:Unit 12.11.
40. Burrer R, Spiridon G, Einius-Haessig S, Richert S, Salmon-Ceron D, Pancino G, et al. Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays. AIDS Res Hum Retrovir. 2006;22(9):865-9. (Pubitemid 44757162)
41. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998;188(2):233-45. (Pubitemid 28357752)
42. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, Tassandin C, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS. 2005;19(17):1947-55. (Pubitemid 41669018)
43. Cagigi A, Nilsson A, De Milito A, Chiodi F. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine. 2008;26(24):3016-25.
44. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9(4):235-45.
45. Louisirirotchanakul S, Beddows S, Cheingsong-Popov R, Shaffer N, Mastro TD, Auewarakul P, et al. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(4):315-20. (Pubitemid 28536039)
46. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002;76(5):2233-44. (Pubitemid 34150691)
47. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS. 2006;20(15):1923-30. (Pubitemid 44427609)
48. Burrer R, Salmon-Ceron D, Richert S, Pancino G, Spiridon G, Haessig S, et al. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J Virol. 2001;75(11):5421-4. (Pubitemid 32448569)
49. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol. 2007;81(12):6548-62. (Pubitemid 46878059)
50. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol. 2009;83(2):1045-59.
51. Andrabi R, Bala M, Kumar R, Wig N, Hazarika A, Luthra K. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. PLoS ONE. 2012;7(8):e43704.
52. Dreyer K, Kallas EG, Planelles V, Montefiori D, McDermott MP, Hasan MS, et al. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retrovir. 1999;15(17):1563-71.
53. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77(20):11212-9. (Pubitemid 37204311)
54. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79(15):9625-34. (Pubitemid 41022306)
55. Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28(2):105-13. (Pubitemid 32971057)
56. Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, et al. Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog. 2010;6(9):e1001084.
57. Wang F-X, Kimura T, Nishihara K, Yoshimura K, Koito A, Matsushita S. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J Infect Dis. 2002;185(5):608-17. (Pubitemid 34171465)